Free Trial

Genus (GNS) Stock Forecast & Price Target

Genus logo
GBX 1,514 -2.00 (-0.13%)
(As of 12/20/2024 12:01 PM ET)

Genus - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
2

Based on 2 Wall Street analysts who have issued ratings for Genus in the last 12 months, the stock has a consensus rating of "Buy." Out of the 2 analysts, 2 have given a buy rating for GNS.

Consensus Price Target

GBX 2,150
According to the 2 analysts' twelve-month price targets for Genus, the average price target is GBX 2,150. The highest price target for GNS is GBX 2,150, while the lowest price target for GNS is GBX 2,150. The average price target represents a forecasted upside of 42.01% from the current price of GBX 1,514.
Get the Latest News and Ratings for GNS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Genus and its competitors.

Sign Up

GNS Analyst Ratings Over Time

TypeCurrent Forecast
12/22/23 to 12/21/24
1 Month Ago
11/22/23 to 11/21/24
3 Months Ago
9/23/23 to 9/22/24
1 Year Ago
12/22/22 to 12/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetGBX 2,150GBX 2,150GBX 2,150GBX 4,500
Consensus Rating
Buy
Buy
Buy
Buy

GNS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GNS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Genus Stock vs. The Competition

TypeGenusMedical Companies
Consensus Rating Score
3.00
2.81
Consensus RatingBuyModerate Buy
News Sentiment Rating
Neutral News

See Recent GNS News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/11/2024Shore Capital
1 of 5 stars
 Reiterated RatingBuy
7/17/2024Deutsche Bank Aktiengesellschaft
3 of 5 stars
 Lower TargetBuyGBX 2,300 ➝ GBX 2,150+24.28%
5/16/2023Peel Hunt
3 of 5 stars
 Reiterated RatingBuyGBX 4,500+76.89%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 12:56 PM ET.


GNS Forecast - Frequently Asked Questions

According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Genus is GBX 2,150, with a high forecast of GBX 2,150 and a low forecast of GBX 2,150.

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genus in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GNS shares.

According to analysts, Genus's stock has a predicted upside of 42.01% based on their 12-month stock forecasts.

Genus has been rated by research analysts at Shore Capital in the past 90 days.

Analysts like Genus more than other "medical" companies. The consensus rating for Genus is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GNS compares to other companies.


This page (LON:GNS) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners